Endocrine Abstracts

Introduction: Pembrolizumab is a programmed death receptor-1(PD-1)-blocking antibody, used in a variety of advanced malignant tumors with promising results, although adverse events are not rare.Case report: We present the case of an adult female, with negative personal and family history of autoimmune diseases, who developed malignant superficial melanoma of right wrist 6 years ago. She was initially treated with surgical resection (lesion and ipsilatera...